We are grateful for everyone involved in LUNAR, the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in metastatic non-small cell lung cancer post-platinum therapy. #lungcancer
https://www.novocure.com/lunar-phase-3-clinical-trial-demonstrates-statistically-significant-and-clinically-meaningful-extension-in-overall-survival-for-patients-with-metastatic-non-small-cell-lung-cancer-after-platinum-based/
Missed the LUNAR presentation? Learn more at our investor event today at 2 p.m. CDT. #lungcancer https://www.novocure.com/lunar-phase-3-clinical-trial-demonstrates-statistically-significant-and-clinically-meaningful-extension-in-overall-survival-for-patients-with-metastatic-non-small-cell-lung-cancer-after-platinum-based/
Happening soon: Primary investigator Ticiana Leal, M.D., of @WinshipAtEmory @EmoryMedicine is presenting the results of our phase 3 LUNAR clinical trial in non-small cell lung cancer, which met its primary endpoint. #ASCO23 #lungcancer https://www.novocure.com/lunar-phase-3-clinical-trial-demonstrates-statistically-significant-and-clinically-meaningful-extension-in-overall-survival-for-patients-with-metastatic-non-small-cell-lung-cancer-after-platinum-based/
Today, we are presenting positive results from the phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields therapy together with standard therapies for the treatment of non-small cell lung cancer at the 2023 @ASCO Annual Meeting. #ASCO23
https://www.novocure.com/lunar-phase-3-clinical-trial-demonstrates-statistically-significant-and-clinically-meaningful-extension-in-overall-survival-for-patients-with-metastatic-non-small-cell-lung-cancer-after-platinum-based/
This #ASCO23 we are sharing patient advocacy groups’ insights. Danielle Hicks from GO2 for Lung Cancer @GO2forLungCancr explains the organization’s important work supporting patients and their loved ones.
During #ASCO23 we are asking patient advocacy groups to share their insights about people living with some of the most aggressive forms of cancer. For Dr. Arif Kamal @arifkamalmd from the @AmericanCancer, partnering is key to realizing their vision.